Press release
Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight
The 7MM Graft Versus Host Disease (GvHD) market has demonstrated substantial growth in recent years, fueled by rising transplant rates, an aging population, and the introduction of innovative therapies such as ZEMAIRA, EQ001, MaaT013, and RGI-2001, among others. According to DelveInsight's comprehensive analysis, key pharmaceutical companies including ICSL Behring, Equillium, Biocon, MaaT Pharma, REGiMMUNE, ReAlta Life Sciences, Ono Pharmaceutical (Deciphera Pharmaceuticals), Medsenic, BioSenic, ASC Therapeutics, Cynata Therapeutics, Evive Biotech (Yifan Pharmaceutical), Ironwood, Medac, and others leading innovation in this space.
DelveInsight's "Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides an in-depth understanding of Graft Versus Host Disease (GvHD), historical and forecasted epidemiology, as well as the Graft Versus Host Disease market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The GvHD market forecast anticipates a CAGR of 8.2% through 2034 over the study period (2020-2034) from USD 1.3 Billion in 2023.
Regionally, the United States represents around 70% of the GvHD market, thanks to favorable reimbursement policies and rapid adoption of new, premium-priced therapies. The EU4 and the UK together account for about 19% of the GvHD market.
Download the GvHD market report to understand which factors are driving the Graft Versus Host Disease therapeutic market @ Graft Versus Host Disease Market Trends [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
The report also analyzes historical and projected epidemiology segmented by total allogenic transplant cases, total Graft Versus Host Disease prevalence, type-specific cases of Graft Versus Host Disease, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, total treated cases of Graft Versus Host Disease, and mortality adjusted treated cases of Graft Versus Host Disease.
DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded the highest incidence of Grade D[IV] Graft-Versus-Host Disease, aligning with patterns observed in hematologic malignancy transplants.
Discover evolving trends in Graft Versus Host Disease patient pool forecasts @ Graft Versus Host Disease Epidemiology Analysis [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Graft Versus Host Disease Treatment Market Report provides insights into current GvHD treatment practices, emerging drugs, market share of individual therapies, and forecasts for the 7MM GvHD market size from 2020 to 2034. Current Graft Versus Host Disease therapies include steroids, NIKTIMVO, JAKAFI, IMBRUVICA, RYONCIL/TEMCELL HS, and ORENCIA, among others.
Graft Versus Host Disease Treatment is evolving from broad immunosuppression to targeted and cell-based therapies. JAKAFI (ruxolitinib), a JAK1/JAK2 inhibitor, is a cornerstone of GvHD treatment and generates substantial revenue due to its proven efficacy in steroid-refractory cases.
DelveInsight's analysis indicates that the GvHD clinical trials market is highly active, with numerous investigational therapies in various stages of development. Notable candidates include ZEMAIRA (CSL Behring), EQ001 (Equillium/Biocon), MaaT013 (MaaT Pharma), RGI-2001 (REGiMMUNE), MC0518 (Medac), RLS-0071 (ReAlta Life Sciences), VIMSELTINIB (Deciphera Pharmaceuticals), ARSCIMED (Medsenic/BioSenic), ASC-930 (ASC Therapeutics), CYP-001 (Cynata Therapeutics), F-652 (Yifan Pharmaceutical), and APRAGLUTIDE (Ironwood), among others.
Unlock which Graft Versus Host emerging Disease drug is expected to capture the largest market share in 7MM by 2034. Visit the Graft Versus Host Disease Market Insights [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
In January 2025, the FDA approved Incyte's and Syndax's Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for the treatment of chronic graft-versus-host disease (GVHD) in adults and pediatric patients based on data from the AGAVE-201 trial. This demonstrates encouraging progress in the graft versus host disease clinical trials market.
Upcoming milestones may include potential label expansions of cellular therapies like mesenchymal stromal cells, which could redefine first-line treatment strategies. However, challenges remain, such as standardizing response criteria across clinical trials and addressing the financial strain associated with chronic graft versus host disease treatment. DelveInsight's report emphasizes that overcoming these challenges will require collaboration among pharmaceutical stakeholders and transplant networks to optimize patient stratification and track outcomes effectively.
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
GvHD Market Overview at a Glance
4.
Executive Summary
5.
Key Events
6.
Disease Background and Overview
7.
Methodology
8.
Epidemiology and Patient Population
9.
Patient Journey
10.
Marketed Drugs
11.
Emerging Drugs
12.
GvHD - 7MM Market Analysis
13.
KOL Views
14.
Unmet Needs
15.
SWOT Analysis
16.
Market Access and Reimbursement
16.1.
The US
17.
Appendix
18.
DelveInsight Capabilities
19.
Disclaimer
20.
About DelveInsight
Related Reports
Graft versus host disease (GvHD) Pipeline Insight [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Graft versus host disease Pipeline Insight provides comprehensive insights about the GvHD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the GvHD companies, including Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK and Amgen among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graft-versus-host-disease-market-is-projected-for-substantial-expansion-from-usd-13-billion-in-2023-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight here
News-ID: 3915489 • Views: …
More Releases from ABNewswire
Mario Serralta & Associates Highlights the Importance of Bilingual Legal Service …
In a city as culturally diverse as Miami, access to bilingual legal services is not just a benefit - it's essential.
Miami Lakes, FL - March 26, 2025 - Mario Serralta & Associates, a law firm dedicated to representing victims of slip-and-fall accidents, is bringing attention to the critical role bilingual representation plays in ensuring justice for Miami's Spanish-speaking population.
"Too often, language barriers prevent injury victims from understanding their legal rights…
Australian Traders Get a Boost as Interosoft Launches Its Most Advanced Market S …
Interosoft [https://izmirsoft.net/], an industry leader in financial technology innovation, has officially released its most advanced market signal tool to date, providing Australian traders with a powerful new resource to navigate today's fast-paced and unpredictable markets.
This latest launch marks a major leap forward in precision trading technology, with Interosoft unveiling a feature-rich platform designed to enhance timing, reduce uncertainty, and offer data-backed confidence for traders across the country. Built for accuracy,…
GAJURA.com - A Premier SEO and Digital Marketing Hub Helping Brands Thrive in th …
In today's digitally-driven business landscape, Gajura.com [http://gajura.com/] emerges as a powerful force in the world of SEO and online marketing, offering tailored solutions that help businesses of all sizes build authority, gain visibility, and drive exponential growth. Backed by years of hands-on expertise, the platform is the brainchild of Gajura Constantin, a respected SEO expert with a passion for performance and precision.
At Gajura.com, the mission is clear: to provide cost-effective,…
Ace Deck Builders | Austin Announces Rebrand: Elevating Outdoor Living with Expe …
Ace Deck Builders | Austin is a trusted name in deck installation and repair, helping homeowners enhance their outdoor spaces with custom designs and high-quality materials. With a commitment to precision and durability, the company offers tailored solutions for both new decks and expert restorations. Whether you're looking to build a brand-new deck or repair an existing one, Ace Deck Builders | Austin delivers exceptional service to create lasting outdoor…
More Releases for Graft
Graft Delivery Devices Market Facts, Figures and Analytical Insights, 2017 to 20 …
Global Graft Delivery Devices Market: Snapshot
Graft delivery relates to the surgically transplantation of a piece of living tissues and the procedure can be highly essential as well as complex at the same time. Consequently, technological advancements have paved way to graft delivery devices that can minimally breach bone, fat, and vascular parts of the body to transfer drugs during plastic and reconstructive surgeries as well as arthroscopic and orthopedic surgeries.…
Glass Graft Polyols Market 2019| BASF SE, Sinopec, Shell, Oltchim, The Dow Chemi …
Market Research Hub (MRH) has actively included a new research study titled “Global Graft Polyols Market” Research Report 2019 to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period until forecast period limit; 2025. In…
Global Vascular Graft Market Growth Analysis Report 2018-2025Global Vascular Gra …
Research Report 2018-2025 on "Global Vascular Graft Market" which provides an outlook of current market value of Vascular Graft Market as well as the expected forecast of Rate on Investment (ROI) with growing CAGR of XX% in Vascular Graft Market by the end of 2025. The report on the global Vascular Graft market uses the top-down and bottom-up approaches to define, analyze, and describe the Vascular Graft market 2018 trends…
Vascular Graft Market Report 2018: Segmentation by Product (Endovascular Stent G …
Global Vascular Graft market research report provides company profile for W. L. Gore & Associates, Inc., C.R. Bard, Inc., MAQUET Holding B.V. & Co. KG (Getinge Group), Cook Medical, Inc., B. Braun Melsungen AG, Medtronic plc, LeMaitre Vascular, Inc., Vascutek Ltd. (Terumo Company) and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to…
Innovation in Bone Graft Techniques Drives the Global Dental Membrane and Bone G …
Dental membrane and bone graft substitutes is used in the bone graft surgeries. Bone graft surgery is required when tooth is lost by accidents, dental disease and old age. According to WHO, Globally, about 30% of people aged 65–74 have no natural teeth and Across the world, 16-40% of children in the age range 6 to12 years old are affected by dental trauma due to unsafe playgrounds, unsafe schools, road…
Global Bone Graft and Substitutes Market: Growing Demand for Bone Graft Substitu …
With only a few companies enjoying dominance, the global bone grafts and substitutes market demonstrates a consolidated vendor landscape. As per Transparency Market Research (TMR), the top three companies including Stryker Corporation, Zimmer, and Medtronic accounted for over 50% of the market in 2014. “The key market players are in a constant competitive state as they vie for sustainable growth and increasing their global footprint,” said a lead TMR analyst…
